INCA, MALLORCA, Spain, April 18, 2011 /PRNewswire/ -- The Board of Directors of Global Immune Technologies, Inc. (OTC QB: GIMU) announces that it has plans to build a production facility in Mallorca, Spain. At a press conference held Friday, 15 April at the offices of Arcis International Trust, S.A. and covered by radio, TV & newspapers from around Europe, officials of our JV partner RenOn, said a factory will be built in an existing building in Inca, Mallorca, Spain. About 20 Million Euros will be invested to produce the RenOn Hybrid Solar Collector. Uwe Vincent, Chief of R&D announced to the press conference that the plant will start operations in August and provide 45 jobs. The project is supported by the Spanish Government and by the employment office, which will also finance training courses for new employees. The press conference was attended by Spanish Senator, Javier Ramis. The innovative new Hybrid Solar Collector panels provide both electricity and heat.
Further information can be obtained by telephoning the Company at +1 406 558 4947 [email protected] or by visiting www.renewunlimited.com or Uwe Vincenz, Telefon: +49 3447 834448 www.iat-remsa.de or email: [email protected]
Safe Harbour Statement
This communication contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Global Immune Technologies, Inc. and members of its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions.
The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE Global Immune Technologies, Inc.